



Suite 424, 800-15355 24th Avenue,
Surrey BC V4A 2H9

1-833-IZOCORP | www.izocorp.com

Izotropic Corporation Announces Cancellation and Issuance of Stock Options

Vancouver, BC, Canada, January 23, 2020 – Izotropic Corporation (CSE: IZO, OTC: IZOZF, FRA: 1R3) (the “Company”) The Company announces that 200,000 stock options previously issued to a Consultant automatically expired 30 days after the end of the contract term on December 31, 2019.

In another transaction, the Company has granted 200,000 stock options to an Advisor at an exercise price of \$0.20 per share for a 5-year term expiring at the close of business on January 22, 2025. The options vest immediately.

On behalf of the Board of Directors,
Robert Thast, CEO

About Izotropic Corp.

Izotropic Corporation (the Company) and its wholly owned U.S. operating subsidiary, Izotropic Imaging Corp. have been established to commercialize the next generation of breast imaging technology for early diagnosis of breast cancer. The Izotropic Breast CT Imaging System produces high resolution breast images in 3D. A single 10 second breast CT scan acquires approximately 500 images, without painful breast compression, providing radiologists with fully 3D viewing of the scanned breast. Mammography scanning requires compression of the breast between 2 imaging plates, resulting in 2D images.

The Company has the exclusive license from the University of California, Davis (UC Davis) to commercialize the technology developed by principal founder and Company director Dr. John M. Boone and researchers at UC Davis. The license includes all intellectual property, trade secrets, patents and patent-pending applications that are the foundation of the Company’s breast CT imaging platform.

Approximately \$20 million in research funding and over 15 years of research and development have been invested in developing this groundbreaking breast CT imaging technology. Research includes a current, fully funded \$2.9M U.S. clinical trial at UC Davis Medical Center.

The Company founders believe that this technology will be a disruptive entry to the market, overcoming many of the challenges faced by existing breast imaging modalities.

Phone: 1-833-IZOCORP
Email: info@izocorp.com
Website: izocorp.com